Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence of small and midsize biotechnology companies drive bio-CDMOs toward becoming end-to-end integrated service providers for better customer value creation. Next-generation biologics require outsourcing in the early stages of development. With limited or no in-house bioprocess development capacity for new modalities, big pharmaceutical firms and small and emerging biotechnology companies seek outsourcing for these services. To support the outsourcing demand, bio-CDMOs expand to provide contract research services, leading to their adoption of the CRDMO model: contract research, development, and manufacturing.
Company profiles included in this research service offer a brief overview of the bio-CDMO’s value proposition and strategic analysis. The report also emphasizes key strategic collaborations and expansion plans across the biopharmaceutical market. Recent expansion activities in the market reflect the increasing role of bio-CDMOs as a strategic partner in developing new modalities. Bio-CDMOs build capacity and capability to support modalities such as cell and gene therapy and mRNA. The biopharmaceutical market is skewed toward these modalities following the success of mRNA technology in COVID-19 vaccines and therapeutics.
GROWTH PIPELINE DIALOG™
Take your first step towards achieving growth-centric solutions with our
Growth Pipeline Dialog™. Speak to our industry experts in a complimentary open discussion that will spark innovative thinking and growth opportunities that will benefit your organization.
